Members Area COST Action number CA17138


This Action brought together Chronic GvHD (cGvHD) researchers across Europe for the first time, creating a network of cross-disciplinary experts in the field.

Working Group 3

Socioeconomics/Quality of life


Dr Hélène Schoemans

Helene has been employed at the UZ Leuven (Belgium) since 2009 as a bone marrow transplantation physician. Her particular interests are Graft versus host disease, Survivorship, Patient Reported Outcomes, eHealth, Chronic care models and Quality of life. She is Chair of the ‘Late Effects Subcommittee’ of the Transplant Complications Working Party of the EBMT (European Society for Bone & Marrow Transplantation).

Dr Hélène Schoemans




Vice Lead

Daniel Wolff




Other working groups


This Working Group will assess the type and amount of biomarker information which is currently available in the literature and assess those which are worthy of further validation and study.

NIH Consensus

The NIH consensus criteria needs to be implemented uniformly if diagnosis and treatment of
cGVHD is to be optimized. The aim of this Working Group will be to aid in both the understanding and
implementation of the NIH Consensus via Training Schools and workshops.


Patients with cGvHD (30-50%) can become refractory to standard therapy, new treatment options and the assessment of current novel therapies are urgently needed to improve the long term outcome and quality of life. In this Working Group the Action will bring together experts in cGVHD and clinical trial development, especially in the realm of cellular therapies with the aim of developing concepts for new approaches including personalized approaches to therapy.

Are you interested
in taking part?

If you would like to join the network, have a general query or any suggestion, please connect with us.

Contact us

Get involved

Do you have a question?

If you have any questions or would like to know more about the project, simply connect with us and we’ll be happy to talk to you.